Article
A phase II study of a human anti-PDGFRα monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Mar 2017
Wagner A J, Kindler H, Gelderblom H, Schöffski P, Bauer S, Hohenberger P, Kopp H-G, Lopez-Martin J A, Peeters M, Reichardt P, Qin A, Nippgen J, Ilaria R L, Rutkowski P
Abstract excerpt
Background: This study evaluated tumor response to olaratumab (an anti-PDGFRα monoclonal antibody) in previously treated patients with metastatic gastrointestinal stromal tumor (GIST) with or without PDGFRα mutations (cohorts 1 and 2, respectively). Patients and methods: Patients received olaratumab 20 mg/kg intravenously every 14 days until disease progression, death, or intolerable toxicity occurred. Outcome...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.